Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

Where this comes from

• Record sourced from PubMed, PMID 36264846.
• Also identified by DOI 10.1371/journal.pone.0276650 and PMC identifier 9584390.
• No licence information is recorded for this record.
• Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.